Why the study?
Does repaglinide or glibenclamide reduce meal-induced platelet activation and endothelial markers in patients with Type 2 diabetes mellitus?
Does repaglinide or glibenclamide reduce meal-induced platelet activation and endothelial markers in patients with Type 2 diabetes mellitus?
Repaglinide, but not glibenclamide, attenuates fasting platelet and endothelial activity in Type 2 diabetes, though neither prevents postprandial platelet activation.
Authors
No takes yet. Share an insight, caveat, or question.
Neither repaglinide nor glibenclamide reduces meal-induced platelet activation in T2DM; challenges postprandial expectations while confirming fasting marker reductions with repaglinide.
Yngen et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: